At the AACR Annual Meeting 2025, PamGene presented six scientific posters showcasing how our kinase activity profiling technology accelerates drug discovery and enhances understanding of cancer biology. These studies demonstrate...Read More
‘s-Hertogenbosch, the Netherlands, March 21, 2024 – PamGene International B.V., an in-vitro diagnostics and biomarker services company developing blood-based immunotherapy guidance tests, announced today the presentations of seven posters from...Read More
‘s-Hertogenbosch, The Netherlands, June 27, 2023 PamGene International B.V., an in-vitro diagnostics and biomarker services company developing a blood-based cancer immunotherapy guidance test called IOpener®, is one of the 51...Read More
PamGene, together with collaborators, presented insightful Applications of our kinase activity profiling technology through Posters and at our Booth # 75Read More
‘s-Hertogenbosch, the Netherlands; Lausanne, Switzerland – January 17, 2023 MAINLINE, a Dutch-Swiss consortium between PamGene International B.V., Alithea Genomics SA and Lausanne University Hospital (CHUV), has been awarded a Eurostars...Read More
‘s-Hertogenbosch, the Netherlands, December 1, 2022 PamGene International B.V., an in-vitro diagnostics and biomarker services company developing blood-based immunotherapy guidance tests, will present the results of its IOpener®-NSCLC test on...Read More
‘s-Hertogenbosch, the Netherlands, July 21, 2022 PamGene International B.V., an in-vitro diagnostics and biomarker services company developing blood-based immunotherapy guidance tests, today announced its IOpener®-NSCLC test has been registered as...Read More
‘s-Hertogenbosch, the Netherlands, July 5th, 2022 PamGene International B.V., an in-vitro diagnostics and biomarker services company developing blood-based immunotherapy guidance tests, today announced its IOpener®-melanoma test has been registered as...Read More
‘s-Hertogenbosch, the Netherlands, March 29th, 2022 PamGene International B.V., an in-vitro diagnostics company focused on the development and commercialization of blood-based immunotherapy response prediction tests, today announced it has received...Read More
“Making the most out of kinase activity data to take scientific research to the next level is what gets me excited” PamGene’s kinase activity profiling data provides scientists with new...Read More
